Abraham Ceesay, Chief Executive Officer and Director of Rapport Therapeutics, Inc. (NASDAQ:RAPP), filed a Form 4 on August 26, 2026, disclosing the sale of 18,921 shares of common stock on August 25, 2026.

Key Highlights

  • Shares sold: 18,921 shares of Rapport Therapeutics common stock disposed of on August 25, 2026.
  • Weighted average price: $49.5723 per share, with individual transactions ranging from $49.03 to $50.03, inclusive.
  • Direct ownership after transaction: 467,187 shares held directly by the reporting person.
  • Indirect holdings: 81,729 shares held indirectly by the Ceesay Family Irrevocable Trust, and 20,729 shares held indirectly by the Dorothy Ceesay Irrevocable Trust.
  • Rule 10b5-1 plan: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2026.

CEO Ceesay's August 2026 Share Sale at Rapport Therapeutics

According to the filing, Abraham Ceesay, who serves as both Chief Executive Officer and Director of Rapport Therapeutics, Inc., sold 18,921 shares of the company's common stock on August 25, 2026. The transaction was coded "S" (sale) in Table I of the Form 4. The filing reported a weighted average sale price of $49.5723 per share, with the shares sold across multiple transactions at prices ranging from $49.03 to $50.03, inclusive. The filing noted that full information on the number of shares sold at each separate price is available from the reporting person upon request.

The filing confirmed that these transactions were carried out under a Rule 10b5-1 trading plan that Ceesay adopted on March 27, 2026. Following the reported sale, Ceesay directly held 467,187 shares of Rapport Therapeutics common stock, according to the filing.

The Form 4 also disclosed indirect beneficial ownership positions. The filing reported 81,729 shares held indirectly through the Ceesay Family Irrevocable Trust, and 20,729 shares held indirectly through the Dorothy Ceesay Irrevocable Trust. The filing was signed by Troy Ignelzi as Attorney-in-Fact and dated August 26, 2026.

What Was Disclosed

The Form 4 filed August 26, 2026, disclosed that Rapport Therapeutics CEO Abraham Ceesay sold 18,921 common shares on August 25, 2026, at a weighted average price of $49.5723, pursuant to a Rule 10b5-1 plan adopted March 27, 2026.